Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 80

1.

Selenium in the prevention of anthracycline-induced cardiac toxicity in children with cancer.

Tacyildiz N, Ozyoruk D, Ozelci Kavas G, Yavuz G, Unal E, Dincaslan H, Atalay S, Ucar T, Ikinciogullari A, Doganay B, Oktay G, Cavdar A, Kucuk O.

J Oncol. 2012;2012:651630. doi: 10.1155/2012/651630. Epub 2012 Oct 16.

PMID:
23125858
[PubMed]
Free PMC Article
2.

Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.

Mavinkurve-Groothuis AM, Groot-Loonen J, Bellersen L, Pourier MS, Feuth T, Bökkerink JP, Hoogerbrugge PM, Kapusta L.

Pediatr Blood Cancer. 2009 May;52(5):631-6. doi: 10.1002/pbc.21913.

PMID:
19127569
[PubMed - indexed for MEDLINE]
3.

Clinical correlation between brain natriutetic peptide and anthracyclin-induced cardiac toxicity.

Lee HS, Son CB, Shin SH, Kim YS.

Cancer Res Treat. 2008 Sep;40(3):121-6. doi: 10.4143/crt.2008.40.3.121. Epub 2008 Sep 30.

PMID:
19688118
[PubMed]
Free PMC Article
4.

Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy.

Pinarli FG, Oğuz A, Tunaoğlu FS, Karadeniz C, Gökçora N, Elbeg S.

Pediatr Blood Cancer. 2005 Apr;44(4):370-7.

PMID:
15602715
[PubMed - indexed for MEDLINE]
5.
6.

N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.

Ekstein S, Nir A, Rein AJ, Perles Z, Bar-Oz B, Salpeter L, Algur N, Weintraub M.

J Pediatr Hematol Oncol. 2007 Jul;29(7):440-4.

PMID:
17609620
[PubMed - indexed for MEDLINE]
7.

Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults.

Dodos F, Halbsguth T, Erdmann E, Hoppe UC.

Clin Res Cardiol. 2008 May;97(5):318-26. doi: 10.1007/s00392-007-0633-6. Epub 2008 Jan 14.

PMID:
18193371
[PubMed - indexed for MEDLINE]
8.

The role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in children: a review of the literature.

Mavinkurve-Groothuis AM, Kapusta L, Nir A, Groot-Loonen J.

Pediatr Hematol Oncol. 2008 Sep;25(7):655-64. doi: 10.1080/08880010802244001. Review.

PMID:
18850478
[PubMed - indexed for MEDLINE]
9.

Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.

Okumura H, Iuchi K, Yoshida T, Nakamura S, Takeshima M, Takamatsu H, Ikeno A, Usuda K, Ishikawa T, Ohtake S, Matsuda T.

Acta Haematol. 2000;104(4):158-63.

PMID:
11279304
[PubMed - indexed for MEDLINE]
10.

Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.

Iarussi D, Indolfi P, Casale F, Martino V, Di Tullio MT, Calabrò R.

Paediatr Drugs. 2005;7(2):67-76. Review.

PMID:
15871628
[PubMed - indexed for MEDLINE]
11.

Assessment of late cardiotoxicity of pirarubicin (THP) in children with acute lymphoblastic leukemia.

Shimomura Y, Baba R, Watanabe A, Horikoshi Y, Asami K, Hyakuna N, Iwai A, Matsushita T, Yamaji K, Hori T, Tsurusawa M; Japanese Childhood Cancer and Leukemia Study Group (JCCLSG).

Pediatr Blood Cancer. 2011 Sep;57(3):461-6. doi: 10.1002/pbc.23012. Epub 2011 Feb 4.

PMID:
21298773
[PubMed - indexed for MEDLINE]
12.

B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children.

Aggarwal S, Pettersen MD, Bhambhani K, Gurczynski J, Thomas R, L'Ecuyer T.

Pediatr Blood Cancer. 2007 Nov;49(6):812-6.

PMID:
17171687
[PubMed - indexed for MEDLINE]
13.

Use of cardiac markers for monitoring of doxorubixin-induced cardiotoxicity in children with cancer.

Pongprot Y, Sittiwangkul R, Charoenkwan P, Silvilairat S.

J Pediatr Hematol Oncol. 2012 Nov;34(8):589-95. doi: 10.1097/MPH.0b013e31826faf44.

PMID:
23018571
[PubMed - indexed for MEDLINE]
14.

Usefulness of N-terminal pro-brain natriuretic peptide to predict postoperative cardiac complications and long-term mortality after emergency lower limb orthopedic surgery.

Chong CP, Ryan JE, van Gaal WJ, Lam QT, Sinnappu RN, Burrell LM, Savige J, Lim WK.

Am J Cardiol. 2010 Sep 15;106(6):865-72. doi: 10.1016/j.amjcard.2010.05.012.

PMID:
20816130
[PubMed - indexed for MEDLINE]
15.

Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines.

Germanakis I, Kalmanti M, Parthenakis F, Nikitovic D, Stiakaki E, Patrianakos A, Vardas PE.

Int J Cardiol. 2006 Apr 4;108(2):212-5. Epub 2005 Nov 10.

PMID:
16290101
[PubMed - indexed for MEDLINE]
16.

Exposure to anthracyclines during childhood causes cardiac injury.

Lipshultz SE.

Semin Oncol. 2006 Jun;33(3 Suppl 8):S8-14. Review.

PMID:
16781284
[PubMed - indexed for MEDLINE]
17.

[Change in plasma N-terminal pro-brain natriuretic peptide in children with Kawasaki disease and its value in clinical practice].

Zhang QY, Du JB, Chen YH, Li WZ.

Zhonghua Er Ke Za Zhi. 2006 Dec;44(12):886-90. Chinese.

PMID:
17254452
[PubMed - indexed for MEDLINE]
18.

Aminoterminal brain natriuretic peptide levels in children and adolescents after Fontan operation correlate with congestive heart failure.

Lechner E, Gitter R, Mair R, Pinter M, Schreier-Lechner E, Vondrys D, Tulzer G.

Pediatr Cardiol. 2008 Sep;29(5):901-5. doi: 10.1007/s00246-008-9225-0. Epub 2008 Apr 8.

PMID:
18392788
[PubMed - indexed for MEDLINE]
19.

Anthracycline cardiotoxicity after breast cancer treatment.

Hershman DL, Shao T.

Oncology (Williston Park). 2009 Mar;23(3):227-34. Review.

PMID:
19418823
[PubMed - indexed for MEDLINE]
20.

[NT-pro-BNP in the evaluation of daunorubicin-indued cardiotoxicity in acute childhood leukemia.]

Hu M, Jiang H, Xia M.

Zhonghua Xue Ye Xue Za Zhi. 2010 Sep;31(9):621-623. Chinese.

PMID:
21122325
[PubMed - as supplied by publisher]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk